On the occasion of the ASCO congress (American society of Clinical Cancer), Pr. Eric Raymond has shown the positive results of a worldwide study of immunotherapy for oesophageal cancer. When tislelizumab, a new immunotherapy antibody, is given with the usual chemotherapy, it significantly improves the patient survival with a 34% lower risk of death.
Our team has just placed its very first Teleflex NaviCurve PICC line, marking a new milestone in the development of this practice. As a reminder,
Saint-Joseph and Marie-Lannelongue Hospitals recognized by Newsweek for the 7th Consecutive Year ! The Newsweek World’s Best Specialized Hospitals 2027 ranking once again recognizes the expertise of our
A New Recognition for Our Hospital ! Paris Saint-Joseph hospital has once again been recognized in Newsweek’s Global Hospital Rating 2027. This international ranking evaluates healthcare